- Home
- ENTA
as of 03-04-2026 3:40pm EST
$15.46
+$0.74
+5.03%
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | WATERTOWN |
| Market Cap: | 486.3M | IPO Year: | 2012 |
| Target Price: | $20.40 | AVG Volume (30 days): | 173.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.42 | EPS Growth: | 29.93 |
| 52 Week Low/High: | $4.09 - $17.15 | Next Earning Date: | N/A |
| Revenue: | $102,814,000 | Revenue Growth: | 16.48% |
| Revenue Growth (this year): | 1.94% | Revenue Growth (next year): | -3.17% |
| P/E Ratio: | -34.95 | Index: | N/A |
| Free Cash Flow: | -32168000.0 | FCF Growth: | N/A |
AI-Powered ENTA Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 71.52%
71.52%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 9, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 9, 2026 · 100% conf.
AI Prediction SELL
1D
-3.68%
$13.32
5D
-7.18%
$12.84
20D
-15.05%
$11.75
Price: $13.83 Prob +5D: 0% AUC: 1.000
0001193125-26-042812
8-K
false000117764800011776482026-02-092026-02-09
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 09, 2026
ENANTA PHARMACEUTICALS, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-35839
04-3205099
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
4 Kingsbury Avenue
Watertown, Massachusetts
02472
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (617) 607-0800
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.01 per share
ENTA
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On February 9, 2026, Enanta Pharmaceuticals, Inc. announced via press release its results for the fiscal quarter ended December 31, 2025. A copy of Enanta's press release is hereby furnished to the Commission and incorporated by reference herein as Exhibit 99.1. Item 9.01 Financial Statements and Exhibits.
Exhibit Number
Description
99.1
Press Release of Enanta Pharmaceuticals, Inc. dated February 9, 2026, reporting Enanta's financial results for the fiscal quarter ended December 31, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ENANTA PHARMACEUTICALS, INC.
Date:
February 9, 2026
By:
/s/ Jay R. Luly, Ph.D.
Jay R. Luly, Ph.D. President and Chief Executive Officer
2025 Q3 Q3 2025 Earnings
8-K Nov 17, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 17, 2025
0001193125-25-284633
8-K
0001177648false00011776482025-11-172025-11-17
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 17, 2025
ENANTA PHARMACEUTICALS, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-35839
04-3205099
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
4 Kingsbury Avenue
Watertown, Massachusetts
02472
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (617) 607-0800
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.01 per share
ENTA
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On November 17, 2025, Enanta Pharmaceuticals, Inc. announced via press release its results for the fiscal quarter and year ended September 30, 2025. A copy of Enanta's press release is hereby furnished to the Commission and incorporated by reference herein as Exhibit 99.1. Item 9.01 Financial Statements and Exhibits.
Exhibit Number
Description
99.1
Press Release of Enanta Pharmaceuticals, Inc. dated November 17, 2025, reporting Enanta's financial results for the fiscal quarter and year ended September 30, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ENANTA PHARMACEUTICALS, INC.
Date:
November 17, 2025
By:
/s/ Jay R. Luly, Ph.D.
Jay R. Luly, Ph.D. President and Chief Executive Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 11, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 11, 2025
0001193125-25-177941
8-K
false000117764800011776482025-08-112025-08-11
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 11, 2025
ENANTA PHARMACEUTICALS, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-35839
04-3205099
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
4 Kingsbury Avenue
Watertown, Massachusetts
02472
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (617) 607-0800
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.01 per share
ENTA
Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On August 11, 2025, Enanta Pharmaceuticals, Inc. announced via press release its results for the fiscal quarter ended June 30, 2025. A copy of Enanta's press release is hereby furnished to the Commission and incorporated by reference herein as Exhibit 99.1. Item 9.01 Financial Statements and Exhibits.
Exhibit Number
Description
99.1
Press Release of Enanta Pharmaceuticals, Inc. dated August 11, 2025, reporting Enanta's financial results for the fiscal quarter ended June 30, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ENANTA PHARMACEUTICALS, INC.
Date:
August 11, 2025
By:
/s/ Jay R. Luly, Ph.D.
Jay R. Luly, Ph.D. President and Chief Executive Officer
Latest Enanta Pharmaceuticals Inc. News
ENTA Breaking Stock News: Dive into ENTA Ticker-Specific Updates for Smart Investing
Compare ENTA vs Leading Stocks
See how ENTA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ENTA Enanta Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.